The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2022 | The role of super-enhancers in multiple myeloma & mechanisms of resistance to IMiDs and T cell-directed therapies
In this discussion, Leif Bergsagel, MD, and Marta Chesi, PhD, Mayo Clinic, Phoenix, AZ, comment on the important role of super-enhancers in multiple myeloma, highlighting the potential of targeting those elements to treat this disease. In addition, Prof. Bergsagel and Dr Chesi discuss the mechanisms of resistance to IMiDs and T cell-directed therapies, talking on the use of animal models to better understand and overcome these mechanisms. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
